UiPath remains a buy, outperforming the S&P 500 with a 53.6% gain since March 2025, driven by operational turnaround. Click ...

UiPath hits an inflection point with stabilizing SaaS, AI roadmap, Maestro platform upsells, top partnerships, and clean balance sheet. See why PATH stock is a buy.

UiPath (NYSE: PATH), a global leader in agentic automation, today announced its UiPath Screen Agent powered by Claude Opus 4.5 achieved a No. 1 ranking on the OSWorld-Verified benchmark, an ...

UiPath CFO and COO Ashim Gupta outlines why the company’s recent progress rests less on agentic AI re-positioning and more on ...

Investors should look at these three options as swing-for-the-fences stock picks.

Figma is challenging Adobe with its lightweight, cloud-based AI design tools. UiPath helps companies automate tasks traditionally performed by human employees with software robots. The slower-growth ...

Zurich Insurance Group AG is a holding company, which engages in the provision of insurance products and related services. It operates through the following segments: Property and Casualty Regions, ...

Zurich Insurance Group AG is a holding company, which engages in the provision of insurance products and related services. It operates through the following segments: Property and Casualty Regions, ...

UiPath Inc. (NYSE:PATH) is one of the AI stocks under $20 to buy now. On December 9, Morgan Stanley analyst Sanjit Singh raised the firm’s price target on UiPath to $19 from $15 with an Equal Weight ...

Kidney function tests are simple blood and urine tests that can identify problems with your kidneys. These tests can estimate your glomerular filtration rate (GFR), which indicates how quickly your ...

Enzymes help with specific functions that are vital to the operation and overall health of the human body. They help speed up chemical reactions and are essential for respiration, digestion, muscle ...